Prolonged complete response after treatment withdrawal in HER2-overexpressed, hormone receptor-negative breast cancer with liver metastases: the prospect of disappearance of an incurable disease

BMC Cancer

Philippe Bougnoux¹  Catherine Barbe²  Flavie Arbion²  Erika Viel¹ 

[1]INSERM, U1069, Nutrition Croissance et Cancer, Faculté de Médecine, Université François-Rabelais, Tours, France

[2]Centre Hospitalier Universitaire Bretonneau, Tours, France

关键词: Complete response;    Cure;    Metastatic;    Cancer;    Breast;   

Others  :  1121051
DOI  :  10.1186/1471-2407-14-690

 received in 2013-11-25, accepted in 2014-09-16,  发布年份 2014

【 摘 要 】

Background

Metastatic breast cancer has consistently been viewed as a non-curable disease. Specific palliative treatments such as chemotherapy and hormone therapy have resulted in a mean overall survival of approximately 30 months. While cases of prolonged complete response have been reported with hormone or trastuzumab monotherapy, rendering metastatic breast cancer a chronic disease, any treatment withdrawal has ineluctably led to relapse. Prolonged remission without any anti-cancer treatment has never been reported to our knowledge.

Case presentation

We report here the unique observation of the spontaneous evolution of two breast cancer patients with synchronous liver metastases who decided to stop trastuzumab after achieving complete response. They were Caucasian women with synchronous liver metastatic breast carcinoma. Both breast cancers reached skin and regional lymph nodes. There were several liver metastases in both patients. They received surgery, radiotherapy and chemotherapy combined with trastuzumab. They decided to stop their treatment, despite guidelines. After a follow-up longer than 20 months, they did not relapse clinically, radiologically, and biologically.

Conclusion

This findings question the belief of the unavoidability of recurrence of metastatic breast cancer, specifically in the liver. It opens up the unprecedented possibility of a cure-like state in exceptional and probably special cases.

【 授权许可】

   
2014 Viel et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Kobayashi T, Ichiba T, Sakuyama T: Possible clinical cure of metastatic breast cancer: lessons from our 30-year experience with oligometastatic breast cancer patients and literature review. Breast Cancer 2012, 19:218-237.
• [2]Park YH, Jung KH, Im SA: Phase III, multicenter, randomized trial of maintenance chemotherapy versus observation in patients with metastatic breast cancer after achieving disease control with six cycles of gemcitabine plus paclitaxel as first-line chemotherapy: KCSG-BR07-02. J Clin Oncol 2013, 31:1732-1739.
• [3]Tawfik H, Rostom Y, Elghazaly H: All-oral combination of vinorelbine and capecitabine as first-line treatment in HER2/Neu-negative metastatic breast cancer. Cancer Chemother Pharmacol 2013, 71:913-919.
• [4]Swain SM, Kim SB, Cortés J: Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol 2013, 14:461-471.
• [5]Polistina F, Costantin G, Febbraro A: Aggressive treatment for hepatic metastases from breast cancer: results from a single center. World J Surg 2013, 37:1322-1332.
• [6]Olson EM, Najita JS, Sohl J: Clinical outcomes and treatment practice patterns of patients with HER2-positive metastatic breast cancer in the post-trastuzumab era. Breast 2013, 22:525-531.
• [7]Extra JM, Antoine EC, Vincent-Salomon A: Efficacy of trastuzumab in routine clinical practice and after progression for metastatic breast cancer patients: the observational Hermine study. Oncologist 2010, 15:799-809.
• [8]Syrios J, Dokou A, Tsavaris N: Sustained complete remission of human epidermal growth factor receptor 2-positive metastatic breast cancer in the liver during long-term trastuzumab (Herceptin) maintenance therapy in a woman: a case report. J Med Case Rep 2010, 4:401. BioMed Central Full Text
• [9]Cardoso F, Fallowfield L, Costa A, ESMO Guidelines Working Group: European School of Oncology, Milan, Italy. Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2011, 22(Suppl 6):vi25-vi30.
• [10]Shepard HM, Lewis GD, Sarup JC: Monoclonal antibody therapy of human cancer: taking the HER2 protooncogene to the clinic. J Clin Immunol 1991, 11:117-127.
• [11]Carter P, Presta L, Gorman CM: Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci U S A 1992, 89:4285-4289.
• [12]Seltzer SE, Getty DJ, Pickett RM: Multimodality diagnosis of liver tumors: feature analysis with CT, liver-specific and contrast-enhanced MR, and a computer model. Acad Radiol 2002, 9:256-269.
• [13]Nguyen DH, Truong PT, Alexander C, Walter CV, Hayashi E, Christie J, Lesperance M: Can locoregional treatment of the primary tumor improve outcome for women with stage IV breast cancer at diagnosis? Int J Rad Oncol Biol Physics 2012, 84:39-45.
• [14]Ruiterkamp J, Voogd AC, Bosscha K, Tjan-Heijnen VC, Ernst MF: Impact of breast surgery on survival in patients with distant metastases at initial presentation: a systematic review of the literature. Breast Cancer Res Treat 2010, 120(1):9-16.
• [15]Gullo G, Zuradelli M, Sclafani F, Santoro A, Crown J: Durable complete response following chemotherapy and trastuzumab for metastatic HER2-positive breast cancer. Ann Oncol 2012, 23:2204-2205.
• [16]Spector NL, Blackwell KL: Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 2009, 27:5838-5847.